WDR76 Drives Hepatocellular Carcinoma Stemness and Progression by Stabilizing CBX5 and Promoting Phase Separation‐Dependent Chromatin Remodeling
Hepatocellular carcinoma (HCC) is characterized by high recurrence, metastasis, and therapeutic resistance, with cancer stem cells (CSCs) contributing substantially to these malignant features. In this study, we identify WD repeat-containing protein 76 (WDR76) as a key oncofetal regulator of liver cancer stemness. Transcriptomic profiling of an in vitro hepatocyte differentiation model revealed that WDR76 is highly expressed in embryonic stem cells, suppressed during hepatocyte maturation, and aberrantly reactivated in HCC. Clinically, WDR76 upregulation correlated with poor differentiation, advanced stage, and reduced patient survival. Functional assays demonstrated that WDR76 enhances CSC-like properties, including self-renewal, invasion, and lenvatinib resistance, while suppressing hepatocytic differentiation. Mechanistically, WDR76 recruits the deubiquitinase USP14 to stabilize the chromatin-binding protein CBX5 by preventing its ubiquitination and degradation. Stabilized CBX5 undergoes liquid-liquid phase separation, promoting heterochromatin condensation and chromatin reprogramming, thereby activating stemness-associated genes. Loss-and gain-of-function studies confirmed CBX5 as an essential downstream effector of WDR76 in driving HCC stemness and tumor progression. Finally, siRNA-loaded nanoparticles targeting WDR76 synergized with lenvatinib to suppress tumor growth in preclinical models. Together, these findings establish a WDR76-USP14-CBX5 axis as a pivotal pathway sustaining CSC phenotypes and nominate WDR76 as a promising diagnostic and therapeutic target in HCC.
Authors
- Mingxin Pan (ORCID: https://orcid.org/0000-0002-9133-3323)
- Xin‐Yuan Guan (ORCID: https://orcid.org/0000-0002-4485-6017)
- Yu Nie (ORCID: https://orcid.org/0000-0002-8546-9873)
- Xiaona Fang (ORCID: https://orcid.org/0000-0001-5325-4686)
- Wenke Yu
- Yi Gao (ORCID: https://orcid.org/0000-0003-3525-0133)
- Yongxin Xie (ORCID: https://orcid.org/0009-0005-5321-1826)
- Qian Yan (ORCID: https://orcid.org/0000-0001-6549-8135)
- Juntao Xie (ORCID: https://orcid.org/0000-0002-0237-3711)
- Yuan Cheng (ORCID: https://orcid.org/0000-0003-4173-293X)
- Qishan Liu (ORCID: https://orcid.org/0009-0007-5920-3696)
- Yishan Peng (ORCID: https://orcid.org/0009-0008-3264-6099)
- Jianning Song
- Wei Yan (ORCID: https://orcid.org/0009-0001-2739-7939)
- Bin Yang
- Yu Zhang
- Siqi Chen
- Yaqing Du (ORCID: https://orcid.org/0009-0007-3909-6176)
- Jingduo Deng
- Yuhai Yuan
- Zeheng Feng
- Xinyi Zhou
Institutions
- Guangzhou University of Chinese Medicine (CN)
- Sun Yat-sen University (CN)
- Sixth Affiliated Hospital of Sun Yat-sen University (CN)
- Zhujiang Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
- State Key Laboratory of Oncology in South China (CN)
- Southern Medical University (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- Advanced Science
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1002/advs.78700
- Primary Topic
- Cancer Cells and Metastasis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Guangzhou Municipal Science and Technology Project